Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO Classification.

ABSTRACT: Cognitive impairment is a common feature among patients with diffuse glioma. The objective of the study is to investigate the relationship between preoperative cognitive function and clinical as well as molecular factors, firstly based on the new 2021 World Health Organization's updated classification of central nervous system tumors. A total of 110 diffuse glioma patients enrolled underwent preoperative cognitive assessments using the Mini-Mental State Examination and Montreal Cognitive Assessment. Clinical information was collected from medical records, and gene sequencing was performed to analyze the 18 most influenced genes. The differences in cognitive function between patients with and without glioblastoma were compared under both the 2016 and 2021 WHO classification of tumors of the

SUBMITTER: Zhang K 

PROVIDER: S-EPMC10844410 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature